BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 28096292)

  • 21. The Roles of MDM2 and MDMX in Cancer.
    Karni-Schmidt O; Lokshin M; Prives C
    Annu Rev Pathol; 2016 May; 11():617-44. PubMed ID: 27022975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Widespread overexpression of epitope-tagged Mdm4 does not accelerate tumor formation in vivo.
    De Clercq S; Gembarska A; Denecker G; Maetens M; Naessens M; Haigh K; Haigh JJ; Marine JC
    Mol Cell Biol; 2010 Nov; 30(22):5394-405. PubMed ID: 20855528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development.
    Migliorini D; Lazzerini Denchi E; Danovi D; Jochemsen A; Capillo M; Gobbi A; Helin K; Pelicci PG; Marine JC
    Mol Cell Biol; 2002 Aug; 22(15):5527-38. PubMed ID: 12101245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mdm4 controls ureteric bud branching via regulation of p53 activity.
    Hilliard SA; Li Y; Dixon A; El-Dahr SS
    Mech Dev; 2020 Sep; 163():103616. PubMed ID: 32464196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. microRNAs and Alu elements in the p53-Mdm2-Mdm4 regulatory network.
    Hoffman Y; Pilpel Y; Oren M
    J Mol Cell Biol; 2014 Jun; 6(3):192-7. PubMed ID: 24868102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rescue of Mdm4-deficient mice by Mdm2 reveals functional overlap of Mdm2 and Mdm4 in development.
    Steinman HA; Hoover KM; Keeler ML; Sands AT; Jones SN
    Oncogene; 2005 Nov; 24(53):7935-40. PubMed ID: 16027727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2.
    Vogel SM; Bauer MR; Joerger AC; Wilcken R; Brandt T; Veprintsev DB; Rutherford TJ; Fersht AR; Boeckler FM
    Proc Natl Acad Sci U S A; 2012 Oct; 109(42):16906-10. PubMed ID: 23035244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation of MDM4 (MDMX) function by p76(MDM2): a new facet in the control of p53 activity.
    Giglio S; Mancini F; Pellegrino M; Di Conza G; Puxeddu E; Sacchi A; Pontecorvi A; Moretti F
    Oncogene; 2010 Nov; 29(44):5935-45. PubMed ID: 20697359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MDM2-MDM4 molecular interaction investigated by atomic force spectroscopy and surface plasmon resonance.
    Moscetti I; Teveroni E; Moretti F; Bizzarri AR; Cannistraro S
    Int J Nanomedicine; 2016; 11():4221-9. PubMed ID: 27621617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas.
    Toledo F; Wahl GM
    Nat Rev Cancer; 2006 Dec; 6(12):909-23. PubMed ID: 17128209
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers.
    Abdel-Fatah TM; Powe DG; Agboola J; Adamowicz-Brice M; Blamey RW; Lopez-Garcia MA; Green AR; Reis-Filho JS; Ellis IO
    J Pathol; 2010 Mar; 220(4):419-34. PubMed ID: 20044801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinct roles of Mdm2 and Mdm4 in red cell production.
    Maetens M; Doumont G; Clercq SD; Francoz S; Froment P; Bellefroid E; Klingmuller U; Lozano G; Marine JC
    Blood; 2007 Mar; 109(6):2630-3. PubMed ID: 17105817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mdm2, but not Mdm4, protects terminally differentiated smooth muscle cells from p53-mediated caspase-3-independent cell death.
    Boesten LS; Zadelaar SM; De Clercq S; Francoz S; van Nieuwkoop A; Biessen EA; Hofmann F; Feil S; Feil R; Jochemsen AG; Zurcher C; Havekes LM; van Vlijmen BJ; Marine JC
    Cell Death Differ; 2006 Dec; 13(12):2089-98. PubMed ID: 16729027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mitochondrial MDM4 (MDMX): an unpredicted role in the p53-mediated intrinsic apoptotic pathway.
    Mancini F; Moretti F
    Cell Cycle; 2009 Dec; 8(23):3854-9. PubMed ID: 19887911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomic aberrations of MDM2, MDM4, FGFR1 and FGFR3 are associated with poor outcome in patients with salivary gland cancer.
    Ach T; Schwarz-Furlan S; Ach S; Agaimy A; Gerken M; Rohrmeier C; Zenk J; Iro H; Brockhoff G; Ettl T
    J Oral Pathol Med; 2016 Aug; 45(7):500-9. PubMed ID: 26661925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tight regulation of p53 activity by Mdm2 is required for ureteric bud growth and branching.
    Hilliard S; Aboudehen K; Yao X; El-Dahr SS
    Dev Biol; 2011 May; 353(2):354-66. PubMed ID: 21420949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The expression of MDM2, MDM4, p53 and p21 in myeloid neoplasms and the effect of MDM2/MDM4 dual inhibitor.
    Eskandari M; Shi Y; Liu J; Albanese J; Goel S; Verma A; Wang Y
    Leuk Lymphoma; 2021 Jan; 62(1):167-175. PubMed ID: 32924682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MDMX (MDM4), a Promising Target for p53 Reactivation Therapy and Beyond.
    Marine JC; Jochemsen AG
    Cold Spring Harb Perspect Med; 2016 Jul; 6(7):. PubMed ID: 27371671
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets.
    Chavez-Reyes A; Parant JM; Amelse LL; de Oca Luna RM; Korsmeyer SJ; Lozano G
    Cancer Res; 2003 Dec; 63(24):8664-9. PubMed ID: 14695178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of oocytes due to conditional ablation of Murine double minute 2 (Mdm2) gene is p53-dependent and results in female sterility.
    Livera G; Uzbekov R; Jarrier P; Fouchécourt S; Duquenne C; Parent AS; Marine JC; Monget P
    FEBS Lett; 2016 Aug; 590(16):2566-74. PubMed ID: 27364741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.